Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317492704> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4317492704 endingPage "122390" @default.
- W4317492704 startingPage "122390" @default.
- W4317492704 abstract "Linagliptin is a new medicament belonging to dipeptidyl peptidase-4 enzyme inhibitors group. The mentioned medication is used to cure type 2 diabetes and is taken orally as a monotherapy or in a co-formulation with metformin. or empagliflozin. Herein, a novel, straightforward, and cost-effective method for linagliptin assay was developed with a workable use of an isoindole derivative. The primary amine moiety present in linagliptin enables its condensation with o-phthalaldehyde to form a fluorescent product in the presence of a sulfhydryl group-containing compound (2-mercaptoethanol) 0.01 % V/V. The isoindole fluorophore yield was monitored at (λexcitation 337.8 nm, λemission 434.3 nm) and all experimental variables were meticulously checked and adjusted. Fluorescence intensity versus linagliptin concentration was plotted to construct the calibration graph, and excellent linearity was achieved at values between 50 and 2000 ng/mL. The validity of the method was verified through a rigorous examination of the ICH guidelines. The method application was successful for linagliptin in different dosage forms, content uniformity study, and monitoring in spiked plasma. The devised technique was demonstrated to be a promising, easy, and quick alternate method for linagliptin assay in clinical study and quality control." @default.
- W4317492704 created "2023-01-20" @default.
- W4317492704 creator A5007842184 @default.
- W4317492704 creator A5028029863 @default.
- W4317492704 creator A5030161707 @default.
- W4317492704 creator A5038274164 @default.
- W4317492704 creator A5066961790 @default.
- W4317492704 creator A5071352742 @default.
- W4317492704 date "2023-04-01" @default.
- W4317492704 modified "2023-10-18" @default.
- W4317492704 title "Application of isoindole fluorophore formation for determination of linagliptin in the sole and co-formulated tablets: Application for plasma assay and content uniformity testing" @default.
- W4317492704 cites W2123946536 @default.
- W4317492704 cites W2790304806 @default.
- W4317492704 cites W2803684055 @default.
- W4317492704 cites W2998846283 @default.
- W4317492704 cites W3109089875 @default.
- W4317492704 cites W3154484168 @default.
- W4317492704 cites W4293788646 @default.
- W4317492704 cites W2911009267 @default.
- W4317492704 doi "https://doi.org/10.1016/j.saa.2023.122390" @default.
- W4317492704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36696863" @default.
- W4317492704 hasPublicationYear "2023" @default.
- W4317492704 type Work @default.
- W4317492704 citedByCount "2" @default.
- W4317492704 countsByYear W43174927042023 @default.
- W4317492704 crossrefType "journal-article" @default.
- W4317492704 hasAuthorship W4317492704A5007842184 @default.
- W4317492704 hasAuthorship W4317492704A5028029863 @default.
- W4317492704 hasAuthorship W4317492704A5030161707 @default.
- W4317492704 hasAuthorship W4317492704A5038274164 @default.
- W4317492704 hasAuthorship W4317492704A5066961790 @default.
- W4317492704 hasAuthorship W4317492704A5071352742 @default.
- W4317492704 hasConcept C10390740 @default.
- W4317492704 hasConcept C121332964 @default.
- W4317492704 hasConcept C134018914 @default.
- W4317492704 hasConcept C185592680 @default.
- W4317492704 hasConcept C21951064 @default.
- W4317492704 hasConcept C2776356293 @default.
- W4317492704 hasConcept C2777180221 @default.
- W4317492704 hasConcept C2778617687 @default.
- W4317492704 hasConcept C2780031085 @default.
- W4317492704 hasConcept C43617362 @default.
- W4317492704 hasConcept C555293320 @default.
- W4317492704 hasConcept C62520636 @default.
- W4317492704 hasConcept C71240020 @default.
- W4317492704 hasConcept C71924100 @default.
- W4317492704 hasConcept C91881484 @default.
- W4317492704 hasConceptScore W4317492704C10390740 @default.
- W4317492704 hasConceptScore W4317492704C121332964 @default.
- W4317492704 hasConceptScore W4317492704C134018914 @default.
- W4317492704 hasConceptScore W4317492704C185592680 @default.
- W4317492704 hasConceptScore W4317492704C21951064 @default.
- W4317492704 hasConceptScore W4317492704C2776356293 @default.
- W4317492704 hasConceptScore W4317492704C2777180221 @default.
- W4317492704 hasConceptScore W4317492704C2778617687 @default.
- W4317492704 hasConceptScore W4317492704C2780031085 @default.
- W4317492704 hasConceptScore W4317492704C43617362 @default.
- W4317492704 hasConceptScore W4317492704C555293320 @default.
- W4317492704 hasConceptScore W4317492704C62520636 @default.
- W4317492704 hasConceptScore W4317492704C71240020 @default.
- W4317492704 hasConceptScore W4317492704C71924100 @default.
- W4317492704 hasConceptScore W4317492704C91881484 @default.
- W4317492704 hasFunder F4320321145 @default.
- W4317492704 hasFunder F4320324457 @default.
- W4317492704 hasLocation W43174927041 @default.
- W4317492704 hasLocation W43174927042 @default.
- W4317492704 hasOpenAccess W4317492704 @default.
- W4317492704 hasPrimaryLocation W43174927041 @default.
- W4317492704 hasRelatedWork W1973992812 @default.
- W4317492704 hasRelatedWork W1983636997 @default.
- W4317492704 hasRelatedWork W1983961744 @default.
- W4317492704 hasRelatedWork W2013621820 @default.
- W4317492704 hasRelatedWork W2018914970 @default.
- W4317492704 hasRelatedWork W2198056047 @default.
- W4317492704 hasRelatedWork W2311943768 @default.
- W4317492704 hasRelatedWork W2772468872 @default.
- W4317492704 hasRelatedWork W4244153422 @default.
- W4317492704 hasRelatedWork W4302022927 @default.
- W4317492704 hasVolume "291" @default.
- W4317492704 isParatext "false" @default.
- W4317492704 isRetracted "false" @default.
- W4317492704 workType "article" @default.